<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">26369984</PMID>
<DateCompleted>
<Year>2017</Year>
<Month>09</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1476-5551</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>30</Volume>
<Issue>5</Issue>
<PubDate>
<Year>2016</Year>
<Month>05</Month>
</PubDate>
</JournalIssue>
<Title>Leukemia</Title>
<ISOAbbreviation>Leukemia</ISOAbbreviation>
</Journal>
<ArticleTitle>Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.</ArticleTitle>
<Pagination>
<MedlinePgn>1184-7</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/leu.2015.246</ELocationID>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Driessen</LastName>
<ForeName>E M C</ForeName>
<Initials>EM</Initials>
<AffiliationInfo>
<Affiliation>Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>de Lorenzo</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo>
<Affiliation>Interfant-99 Trial Data Center, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Campbell</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Chilean National Pediatric Oncology Group, PINDA, Roberto del Rio Hospital, Universidad de Chile, Santiago, Chile.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Felice</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Department of Pediatric Hematology/Oncology, Hospital de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires, Argentina.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Ferster</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Hemato-Oncology, Hôpital Unviversitaire des Enfants Reine Fabiola (ULB), Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hann</LastName>
<ForeName>I</ForeName>
<Initials>I</Initials>
<AffiliationInfo>
<Affiliation>UK Children's Cancer Study Group, Great Ormond Street Hospital for Children, London, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Vora</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Department of Paediatric Haematology, Sheffield Children's Hospital, Sheffield, UK.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Hovi</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Nordic Society of Paediatric Haematology and Oncology, University of Helsinki, Helsinki, Finland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Escherich</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>University Medical Center Hamburg-Eppendorf, Clinic of Pediatric Hematology and Oncology, Hamburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Li</LastName>
<ForeName>C K</ForeName>
<Initials>CK</Initials>
<AffiliationInfo>
<Affiliation>Hong Kong Paediatric Haematology and Oncology Study Group, Prince of Wales Hospital, Hong Kong, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Mann</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>St. Anna Children's Cancer Research Institute and St. Anna Children's Hospital, Department of Pediatrics, Medical University School, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Leblanc</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Departement of Pediatric Hematology, Hôpital Robert-Debré, Paris, fort he FRALLE group, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Locatelli</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo>
<Affiliation>Associazione Italiana Ematologia Oncologia Pediatrica, Italy Bambino Gesù Children's Hospital, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Biondi</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
<AffiliationInfo>
<Affiliation>Associazione Italiana Ematologia Oncologia Pediatrica, Italy Bambino Gesù Children's Hospital, Rome, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Rubnitz</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>St Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Schrappe</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Berlin-Frankfurt-Münster Study Group, Hannover, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Silverman</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
<AffiliationInfo>
<Affiliation>Dana-Farber Cancer Institute ALL Consortium, Boston, MA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Stary</LastName>
<ForeName>J</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Czech Pediatric Haematology, Prague, Czech Republic.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Suppiah</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Australian and New Zealand Children's Haematology and Oncology Study Group, North Adelaide, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Szczepanski</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo>
<Affiliation>Polish Pediatric Leukemia and Lymphoma Study Group, and Department of Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, Katowice, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Valsecchi</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo>
<Affiliation>Interfant-99 Trial Data Center, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Pieters</LastName>
<ForeName>R</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.</Affiliation>
</AffiliationInfo>
<AffiliationInfo>
<Affiliation>Dutch Childhood Oncology Group, The Hague, the Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016422">Letter</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2015</Year>
<Month>09</Month>
<Day>15</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Leukemia</MedlineTA>
<NlmUniqueID>8704895</NlmUniqueID>
<ISSNLinking>0887-6924</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Leukemia. 2017 Dec;31(12 ):2854</RefSource>
<PMID Version="1">29210366</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007223">Infant</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007231">Infant, Newborn</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054198">Precursor Cell Lymphoblastic Leukemia-Lymphoma</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D012008">Recurrence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>9</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>9</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2017</Year>
<Month>9</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">26369984</ArticleId>
<ArticleId IdType="pii">leu2015246</ArticleId>
<ArticleId IdType="doi">10.1038/leu.2015.246</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>J Clin Oncol. 2010 May 10;28(14):2339-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20385996</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Pediatr Blood Cancer. 2009 Jul;52(7):808-13</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19229974</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 1999 Aug 15;94(4):1209-17</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10438708</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2010 Oct 14;116(15):2644-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20592248</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2012 Apr;26(4):682-92</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22015773</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2015 Feb;29(2):290-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">24888273</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2014 Apr;28(4):761-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23958920</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2007 Jul 21;370(9583):240-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17658395</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2008 Dec;22(12):2142-50</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18818707</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Blood. 2004 Dec 1;104(12):3527-34</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15297313</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer Cell. 2011 Jul 12;20(1):53-65</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21741596</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Cancer. 1998 Apr 1;82(7):1387-95</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9529033</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Oncol. 2011 Jan 10;29(2):214-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21135279</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Haematologica. 2013 Jun;98(6):937-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">23403319</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Leukemia. 2006 Aug;20(8):1368-76</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16761017</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>